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ABSTRACT

An ultra sensitive method for detection of biomolecules
includes the step of providing a plurality ofbioreceptor functionalized nanoparticle pro bes. The nanoparticles can include
metal, semiconductor, radioactive isotope or fluorescent dye
molecules. A sample solution suspected of including the target is contacted with the probes, wherein if present, the target
binds to the bioreceptor. After such binding a separating step
follows. In the separating step, probes having the target bound
thereto are separated from pro bes not having the target bound
thereto. In one embodiment probes having the target bound
thereto are then decomposed to generate ions, or broken into
discrete radioactive isotopes or fluorescent dye molecules to
form a solution including a large plurality of metal ions,
radioactive isotopes or dye molecules. A concentration of
ions, radioactive isotopes, or dye molecules in the solution is
then determined and using this information the concentration
of the target in the original sample solution is determined.

14 Claims, 4 Drawing Sheets
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DETECTION OF BIOTARGETS USING
BIORECEPTOR FUNCTIONALIZED
NANOPARTICLES

to stable quantum dots and nanoparticles. Quantum dots have
high quantum yields, high molar extinction coefficients, high
resistance to photobleaching and exceptional resistance to
photo- and chemical degradation. Due to these exceptional
optical properties, quantum dots have become one of the most
interesting materials for bioimaging, labeling, and sensing.
Other types of nanoparticle materials, such as gold and silver,
exhibit some other unique size-dependent optical properties
such as surface plasmon resonance (SPR). The extinction
coefficient of metal nanoparticles is orders of magnitude
higherthan typical organic molecules; therefore, low concentration detection of DNAs based on color change of gold
nanoparticle-DNA probe conjugates has been developed.
Another important optical property of metal nanoparticles,
the surface enhanced Raman scattering, is also being studied
for ultra low level detection of biomolecules.
In addition to the development of labeling materials that
can lead to lower detection limit, new techniques and methodologies to concentrate the analyte molecules and/or
amplify the analyte concentration have also been reported. An
example of this approach is the barcode detection of proteins
and DNAs using gold nanoparticles and magnetic microparticles developed by Mirkin et al. (Nam, J; Park, S.; Mirkin, C.
A. "Bio-barcodes based on oligonucleotide-modified nanoparticles" J. Am. Chem. Soc. 2002, 124, 3820) The magnetic
microparticles are used as a tool to concentrate analyte molecules in solution by applying magnetic field. To detect the
analyte molecules, multiple bar code DNA molecules are
attached to the gold nanoparticle that is conjugated to the
detector molecule. The detection of the analyte molecule is
realized indirectly by measuring the amount of the bar code
DNA molecules attached to gold nanoparticles. To increase
the detection limit, the concentration of DNA barcode can be
increased by PCR amplification. Using the bio-barcode
method, Mirkin et al. has achieved detection limits for DNA
molecules at the attomolar range (10- 13 M) or lower. Similar
approach has been demonstrated to detect prostate specific
antigens (PSA) at attomolar concentration. Another extensively explored research area for protein detection is the use
of DNA aptamers and PCR amplification technique. Specific
binding towards a target protein is created by simultaneous
binding of two DNA aptamers to two different sites of the
same protein. Ligation of the two-closely positioned DNA
aptamers followed by PCR amplification can lead to detection
of target proteins at a level as low as zeptomole (10- 21 ) range.
Despite significant progress, there is a strong and urgent
need to develop more sensitive, reliable and low cost techniques for biomolecular detection and analysis at ultra low
level. Although the bar-code method developed by Mirkin et
al. has pushed the detection limit beyond the attomolar range,
this method involves the use of expensive biomolecules
(DNA) and rather sophisticated procedures and analytical
instrumentation. Moreover, the amplification effect of the
bar-code method is limited to the number of DNA barcodes
that can be attached to the nanoparticle surface.
Regarding the fluorescence detection technique, the fluorescence of organic dyes and quantum dots is often affected
by the chemical environment of the sample solution, and such
effect could be further manifested at ultra low concentration.
Although surface enhanced Raman scattering has shown
promising potential for label-free trace detection of biomolecules, the Raman enhancement effect is not well understood
and further study is needed before a routine assay method can
be developed from this effect. For the DNA aptamer ligation
method, the biggest problem is that PCR amplification is
needed for the analysis and the type of proteins that can be
detected using this method is relatively limited.

CROSS-REFERENCE TO RELATED
APPLICATIONS
The present application incorporates by reference in its
entirety and claims priority to U.S. Provisional Patent Application Ser. No. 60/862, 125 filed Oct. 19, 2006, entitled "Ultra
Sensitive Detection ofBiotargets Using Ions, Discrete Radioactive Isotopes or Discrete Fluorescent Dye Molecules
Derived from Bioreceptor Functionalized Nanoparticles" and
U.S. Provisional Patent Application Ser. No. 60/887,889 filed
Feb. 2, 2007, entitled "Ultra Sensitive Detection ofBiotargets
Using Ions, Discrete Radioactive Isotopes or Discrete Fluorescent Dye Molecules Derived from Bioreceptor Functionalized Nanoparticles".
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
The U.S. Govermnent may have certain rights to the invention based on National Science Foundation Career Award
DMR 0552295, and DMI 0506531.
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FIELD OF THE INVENTION
The present invention relates to systems and methods of
detecting biotargets using bioreceptor functionalized nanoparticles.
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BACKGROUND OF THE INVENTION
Many medical diagnosis processes are based on the detection of biomarker molecules such as proteins, antibodies,
enzymes, DNA or RNA that are often uniquely associated
with a particular disease. When diseases such as cancer
appear in a human body, the human body is known to produce
levels of certain chemicals that are much lower, or non-existent, in a healthy human being. For example, the diagnosis of
prostate cancer is initially based on the concentration of a
protein called PSA in the body. When the concentration of
PSA exceeds a certain normal range, the doctor will generally
suggest other more direct tools such as biopsy and imaging
techniques to confirm the diagnosis of prostate cancer.
Another example is breast cancer. Breast cancer patients are
known to have much higher level of a certain enzyme called
carbonic anhydrase. The detection of an unusually high level
of this enzyme can provide the initial tool for breast cancer
diagnosis.
The accurate detection of biomolecules at extremely low
levels is vital for early diagnosis of diseases. Regarding many
cancers and other diseases, if diagnosed early, the chance for
successful cure or treatment is much higher than being diagnosed at later stages. Enormous research efforts have been
and are continuously being pursued toward techniques and
tools for biomolecule detection at ultra low levels. For
example, enzymes, fluorescent dye molecules, and radioactive isotopes have been used extensively for bioconjugation
and bioassays. Among the different biolabels, fluorescent dye
molecules have received much attention due to the high sensitivity common to fluorescence detection. Although fluorescent dye molecules display shortcomings such as photobleaching, instability, and sensitivity to environmental
conditions such as pH variation, some of these problems are
being overcome by introducing highly luminescent and pho-
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Therefore, a facile and economic method that allows the
detection of a wide range ofbiomarker and other biologically
significant target molecules at ultra low concentration is
needed preferably in a quantitative manner.

A system for determining the presence of biomolecule
targets includes a vessel where a sample solution suspected of
containing the targets and a plurality ofbioreceptor functionalizednanoparticle probes and a solid substrate for selectively
binding targets-probe conjugates or target free probes is contained. Target-probe conjugates form and a solid substrate
bound with either to a target-probe conjugates or target free
probes, and a complementary solution forms. The system also
includes a separation device to separate the complementary
solution from the substrate. The system also includes a
reagent for breaking down the nanoparticles of the probes of
either the probes attached ultimately to the substrate or the
probes in the complementary solution where the reagent
causes the formation of signal moieties from the nanoparticles of the probes. Both groups of probes, those with and
those without bound targets can be separately mixed with
reagents and broken down to signal moieties. The system also
includes a device to measure a parameter of the solution or
solutions of signal moieties. The substrate can be in the form
of a plate or particles. The separation device can be a filter,
chromatography column, or centrifuge. The reagent to form
the signal moieties can be an oxidizer in solution when the
nanoparticles are metal to form metal ions as signal moieties.
The parameters can be measured using an atomic absorption
or a mass spectrometer.

SUMMARY OF THE INVENTION
This Summary is provided to comply with 37 C.F.R. §1.73,
requiring a summary of the invention briefly indicating the
nature and substance of the invention. It is submitted with the
understanding that it will not be used to interpret or limit the
scope or meaning of the claims.
A method for detection of biomolecule targets that
includes the steps of: providing a plurality of bioreceptor
functionalized nanoparticles to act as probes of the target;
contacting a sample solution suspected of including the targets with the probes where any targets in the sample solution
bind to the probes; separating the probes into a first group of
probes bound to targets and a second group of probes without
bound targets; and breaking down the probes in one group or
separately breaking down the probes in both groups, to
release a plurality of signal moieties forming at least one
signal moiety solution; measuring a parameter of the signal
moieties in the signal moiety solutions; and determining a
presence of targets in the sample solution from the measured
parameter. The nanoparticles can be composed of metal,
semiconductor, radioactive isotopes or fluorescent dye molecules and the bioreceptor is adapted for binding the probes to
the targets where the nanoparticles of the probes in a separated group of probes can be broken down to a plurality of
ions, discrete radioactive isotopes or discrete fluorescent dye
molecules. When the nanoparticles are a metal the breaking
down step is the oxidation of the metal to metal ions. Metals
that can be used include gold, silver, cadmium or an alloy
thereof. The bioreceptor can be an antibody, DNA, proteins
including enzymes, cells or cell components that bind
strongly to a biomolecular targets which can be one or more
biomarkers of at least one type of cancer. The sample solution
can be a bodily fluid or a fluid derived from body tissue.
Separation of the group of probes bound to the targets from
probes that are free of targets after contacting the sample
solution with the probes can be carried out by binding the
targets to a substrate surface before contacting the targets
with the probes and separating the substrate bound to the
target that also binds to a probe from probes that are in excess
and do not bind to the targets which remain in solution.
Alternately, the probes and sample solution can be contacted
and a substrate included where probes that have not bonded to
targets are bound to the substrate surface, and separating the
substrate from probes bound to targets that remain in solution.
The step of measuring a parameter can be measuring a
concentration of ions in a signal moiety solution by atomic
absorption spectroscopy or by mass spectroscopy. The presence of the target in the sample solution can be calculated
using values for an average size of the nanoparticles and an
average number ofbioreceptors attached to a probes. In one
embodiment the presence can be determined quantitatively
where calculations are performed using a value for the parameter of the signal moiety solution where probes bound to
targets are broken down. In another embodiment the concentration of targets in the sample solution can be calculated by
the difference in the number of probes contacted with the
sample solution and the number or probes determined from
the parameter of the signal moieties from the braking down of
probes in the separated group of probes that did not bind to
targets in the sample solution.
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BRIEF DESCRIPTION OF THE DRAWINGS

30

35

40

45

50

55

A fuller understanding of the present invention and the
features and benefits thereof will be obtained upon review of
the following detailed description together with the accompanying drawing, in which:
FIG. 1 is a schematic of a system of determining the presence of biomolecule targets according to an embodiment of
the invention.
FIG. 2 is a plot of gold ion concentration formed from the
amplification assay according to an embodiment of the invention where the target PSA, in concentrations from 0.01 to 30
ng/mL, was contacted with bioreceptors conjugated to gold
nanoparticies with ions analyzed by GFAAS.
FIG. 3 is a plot of two different series of assays of PSA
using the amplification assay according to an embodiment of
the invention, using bioreceptors conjugated to gold nanoparticles with ions analyzed by GFAAS.
FIG. 4 is a reaction schematic for the preparation of a
bioreceptor conjugated to gold nanoparticle according to an
embodiment of the invention.
FIG. 5 is a plot ofa series of amplification assays of0.01 to
30 ng/mL PSA solutions according to an embodiment of the
invention, using bioreceptors conjugated to quantum dots as
nanoprobes with ions analyzed by ICP-MS.
FIG. 6 is a plot of a series of amplification assays of
cytokeratine from lysed cell samples of 0.16, 1.6, and 15
µg/mL according to an embodiment of the invention, using
bioreceptors conjugated to gold nanoparticles.
DETAILED DESCRIPTION

60

65

An ultra sensitive method for detection of target biomolecules includes the step of providing a plurality ofbioreceptor
functionalized nanoparticle probes. The nanoparticles can
comprise metal, semiconductor, radioactive isotope or fluorescent dye molecules. The bioreceptors are adapted for binding to a target biomolecule. Binding can be covalent bonding,
ionic bonding, complexation, hydrogen bonding, dipole-dipole interaction, van der Waals forces or any combination of
such associations between at least one site of the target and at
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least one site of the bioreceptor as long as the binding is
sufficiently strong to essentially form a target-probe associate
with essentially complete binding of the targets where binding is maintained during any separating, washing or other
steps of isolation of target-probe moieties during the method.
A sample solution suspected of including the target is contacted with the probes, wherein if present, the target binds to
the bioreceptor.
Such a bioassay can be carried out in a fashion employed in
enzyme-linked immunosorbent assays (ELISA) or DNA chip
multi-array analysis. In one embodiment, the method comprises the association of the target to a substrate surface fixed
second bioreceptor followed by introduction of an excess of
probes with subsequent separation of substrate fixed targets
bound to the probe from probes free of the target. In another
embodiment the targets are bound to probes in a solution
containing excess probes followed by fixing probe bound
targets to a substrate surface with fixed bioreceptor and subsequent separation of substrate fixed targets bound to the
probe from unbound probes. In another embodiment of the
invention a solution of target bound probes and excess probes
are contacted with a substrate surface fixed target such that
excess probes can be bound to the surface but target bound
probes in solution can be removed from the excess probes
bound to the substrate. The substrate fixed target can be the
same or different than the target analyte but the relative binding constants of probes to the target analyte and to the substrate bound target should not promote the debonding of the
probe from the target analyte. The substrate can be a plate or
a particle that can be readily isolated from or washed of a
solution containing the probes. In all embodiments the separating step comprises separation of probes having the target
bound thereto from probes not having the target bound
thereto.
In one embodiment of the invention probes having the
target bound thereto are subjected to a step of "breaking
down" which can be decomposition to generate a plurality of
moieties to provide a signal, also referred to as "signal moiety" and include ions, discrete radioactive isotopes or discrete
fluorescent dye molecules to form a solution comprising a
large plurality of metal ions, radioactive isotopes or dye molecules. A concentration of signal moieties in the solution is
then determined and this information is used to determine the
concentration of the target in the original sample solution.
Amplification of the signal occurs when the signal provided
by the signal moieties of the decomposed probe is significantly greater than that provided by the intact probe. In
another embodiment of the invention, probes that were not
bound to the targets are broken down and analyzed wherein
the difference, the decrease, in a signal from that where none
of the provided probe has been bound to the target is used to
determine the presence or quantity of the target in the sample.
In this manner the detection can be carried out well above the
detection limits of the analytical technique and when the
sensitivity of the technique is sufficiently high, small target
concentrations can be determined by the difference in measurement.
Bioreceptor probes can include, but are not limited to,
antibody, DNA, proteins including enzymes, cells or cell
components, such as biometric probes. Biometric probes can
include molecular imprint antibodies, DNA-based aptamers,
and peptide nucleic acids (PNA). Bioreceptors can be any
moiety known to associate strongly to the target biomolecule.
In some embodiments of the invention the bioreceptor should
also associate selectively to the target biomolecule. For
example, an operable DNA (gene) probes can be based on the
well known hybridization process ofjoining of a single strand
of nucleic acid with its complementary probe sequence. The

operation of an antibody probe can be through a more general
binding process that does not involve hybridization.
Binding of various bioreceptors to solid surfaces, such as
the surface of metal nanoparticles, is well known. For
example, complexes between DNA and negatively charged
gold nanoparticles have been studied for many years (See, for
example, Mirkin et al., Nature 382:607-609 (1996); Alivisatos et al., Nature 382:609-611 (1996)). Many creative
schemes have exploited gold nanoparticles covalently functionalized with DNA sequences to bind specific target DNA
sequences, either for nano-assembly or for oligonucleotide
sensing (See, for example, Elghanian et al., Science 277:
1078-1081 (1997); Taton et al., Science 289:1757-1760
(2000); Park et al., Science 295: 1503-1506 (2002); Cao et al.,
Science 297:1536-1540 (2002); Maxwell et al., J. Am. Chem.
Soc. 124:9606-9612 (2002); Dubertret et al., Nat. Biotech.
19:365-370 (2001); Sato et al., J. Am. Chem. Soc. 125:81028103 (2003); Mirkinetal.,Nature 382:607-609 (1996);Alivisatos et al., Nature 382:609-611 (1996); Chakrabarti et al., J.
Am. Chem. Soc. 125:12531-12540 (2003).
Targets are generally biochemical substances, such as proteins, metabolites, nucleic acids, biological species or living
systems, such as bacteria, virus or related components which
are generally at ultra-trace levels in samples provided. In the
case of medical diagnostic applications, the sample solution
can be derived from tissues (for example using biopsy), blood
or other bodily fluids (such as urine or saliva).
In embodiments of the invention, ultra sensitive detection
is provided by signal amplification resulting from the chemical decomposition of solid nanoparticles having targets
bound thereto into ions. This amplification is referred to
herein as "atomic or molecular amplification". The atomic or
molecular amplification factor is essentially equal to the number of atoms or molecules in the nanoparticle. In one embodiment, atomic absorption spectroscopy such as graphite furnace atomic absorption spectroscopy (GFAAS) is used to
determine the concentration of ions. Alternatively, inductive
coupled-plasma mass spectroscopy (ICP-MS) or other types
of mass spectroscopy, or other types of analytical techniques
which allow sensitive detection of ions may also be used. In
an alternate embodiment of the invention, the nanoparticles
comprise fluorescent dye molecules which are released from
the nanoparticles and their concentration determined by fluorescent spectroscopy. In yet another embodiment of the
invention, the nanoparticles comprise radioactive isotopes
which after release from the nanoparticles have their concentration determined by measuring the radioactivity of the solution.
As an example for an ion-based embodiment of the present
invention, assuming the nanoparticles are 40 nm, gold, and
spherical, if 100 copies of capture antibody-antigen-nanoparticle labeled detector antibody complexes are formed on the
microtiter plate in a sandwich ELISA assay, the amount of
gold ions released from the microtiter plate after decomposition is 2x 10 8 , corresponding to approximately 10- 15 moles. If
the amount of solvent used to decompose the gold nanopar~icle is l.imite~ to 1-10 §LL, the total concentration of gold io~s
m solut10n will be 10- to 10- 10M (100 s to 10 s ofppt). This
concentration is around or very close to the detection limit of
GFAAS or ICP-MS.
The present method thus uses nanoparticles, for example
metal nanoparticles such as gold, silver or other metals. The
present invention is generally described herein with respect to
gold nanoparticles, which act as a signal transducer to measure the concentration ofbiomolecule targets in solution. The
procedure according to an embodiment of the invention is
described with reference to FIG. 1. Gold nanoparticles in the
nanometer size range (1 to 1,000 nm), such as the size range
of 10-100 nm, are modified to be functionalized with a bioreceptor, such as antibody, DNA, proteins including enzymes,
cells or cell components that will recognize and bind to the
specific target biomolecules to be detected in a sample soluti on. The size of the nanoparticles should be known, or can be
determined by methods including transmission electron
microscopy (TEM), and is preferably in a narrow size range.
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The mixing of the nanoparticles with the sample solution
allows the biomolecule targets, if present, to bind with the
gold nanoparticles. Once bound, the probes are referred to
herein as "conjugated nanoparticles" or "target-probe conjugates". In one embodiment of the invention there can be an
excess of nanoparticles relative to the target such that nonconjugated nanoparticles remain after the mixing step. In
another embodiment of the invention no excess of nanoparticles relative to the target is used such that no non-conjugated
nanoparticles remain after the mixing.
The conjugated nanoparticles can be separated from any
non-conjugated nanoparticles through ultrafiltration, or other
methods. Thus, only the conjugatednanoparticles will remain

mately 6 pg. This corresponds to a number of gold nanoparticles around 10- 19 mo! for gold nanoparticle with a 40 nm
diameter. According to a one to one nanoprobe-antigen binding, the detection limit for biomarkers could reach 10 19 mo!,
or approximately 100 fg/mL for a sample volume of 100 µL.
When the nanoparticle size is further increased to 100 nm,
each nanoparticle will contain about 30 million gold atoms,
which means the detection limit can be further decreased. The
sensitivity ofGFAAS differs for different metals. Some metals such as silver and cadmium are much more sensitive than
gold. The sensitivity of Cd is ten to one hundred fold more
sensitive than gold. If CdSe nanoparticles are used as nanoprobes, the detection limit will be decreased further.

10

TABLE 1
The instrument sensitivity ofGFAAS and calculated detection limit of the proposed atomic
amplification assay using different types ofnanoparticle nanoprobes

Detection limit in
Element

absolute mass (pg)

40 nm nanoprobe

100 nm nano probe

19

Au
Ag
Cd

in solution. The number of target biomolecules bound per
nanoparticle may be determined based on a particular type of
nanoparticles and this number may be used as a calibration
point for the real sample analysis. For example, if each nanoparticle includes a single bioreceptor probe, the conjugated
nanoparticles will have a single target bound thereto.
In the case of metal or semiconducting nanoparticles, the
conjugated nanoparticles are then chemically decomposed.
For example, for gold nanoparticles, the conjugated gold
nanoparticles can be treated with an iodine/potassium iodide
solution. This solution will oxidize gold atoms into gold
cations, gold (I) or gold (III), to form an ion comprising
solution. The concentration of gold cations is preferably
determined by atomic absorption spectroscopy. However, as
disclosed above, alternatively, inductive coupled-plasma
mass spectroscopy (ICP-MS) other types of mass spectroscopy, or other types of analytical techniques that allow sensitive detection of metal ions may be used. For nanoparticles
which release radioactive isotopes and fluorescent dye molecules after suitable treatment, appropriate analytical techniques, such as radioactivity detection and spectroscopy
methods, respectively, may be used for detection.
When the size and shape of a nanoparticle is known, the
number of atoms per nanoparticle can be calculated. The
number of radioactive isotopes or dye molecules that each
nanoparticle contains may be obtained by standard radioactivity or chemical analysis. Using this number, the concentration of the conjugated nanoparticles can be deduced. Since
the numberofbiomolecule targets bound to eachnanoparticle
can be determined in a calibration study, the concentration of
the biomolecule targets in the sample solution may be calculated.
In one embodiment, the ability to detect the decomposed
nanoparticles, for example metal nanoparticle depends on the
minimal detectable quantity of that ion by a specific analytical technique. The embodiment of the invention using metal
nanoparticles permits analysis by GFAAS to very low concentrations. Table 1, below, gives the potential detection limit
using different nanoparticles. For example, the absolute mass
detection limit of GFAAS for elemental gold is approxi-

Detection limit of atomic amplification assay in absolute number
ofbiomarker when using a:

0.4
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10,000 (10- mol, or 100 fg/mL) 1,000 (10-20 mol, or 10 fg/mL)
1,000 (10-20 mol, or 10 fg/mL)
100 (10-21 mol, or 1 fg/mL)
1,000 (10-20 mol, or 10 fg/mL)
100 (10-21 mol, or 1 fg/mL)

As noted above, the inventive method can be used to detect
ultra low concentration ofbiomolecule targets in sample solution. For example, a 40 nm spherical gold nanoparticle solution with a concentration of 10- 12 M (1 picomolar) where the
nanoparticles are bound to biomolecule targets in a one-toone ratio would be very difficult if not impossible to detect by
current spectroscopic means. However, each spherical gold
nanoparticle with a core diameter of 40 nm can yield about 2
million gold atoms per nanoparticle. Thus, the decomposition
of the gold nanoparticles yields a gold cation concentration of
2 µm (lx10- 12 Mx2xl0 6 ). Such a concentration of gold ions
can be easily and accurately detected by atomic absorption
spectroscopy or other methods. The detection limit can be
further lowered by the use of larger nanoparticles.
More specifically, the atomic or molecular amplification
effect and the detection limit of the present invention are
primarily determined by the following three (3) factors:
(1) the intrinsic binding affinity between the receptor and
target molecules (for example antibody and antigen molecules, or the complementary DNA strands);
(2) the instrumental detection limit of the corresponding
element; and
(3) the size and size distribution of the nanoparticles.
Essentially, the ultimate detection limit of any bioassay is
determined by the binding affinity of the receptor and target
biomolecules. For example, different antibodies have different binding affinities for different antigens, generally varying
from 109 to 10 12 M- 1 . The affinity of the conjugated antibody
to nanoparticles is also affected by the conjugation process.
The second limiting factor that can determine the detection
limit and sensitivity of the bioassay method according to the
invention is the intrinsic instrumental detection limit, such as
GFAAS and ICP-MS. For ultra trace analysis of metal and
metal ions, currently GFAAS and ICP-MS are the two most
sensitive techniques. Although the detection limit ofICP-MS
is generally 100-1000 times lower than GFAAS, currently
commercial available ICP-MS are mainly configured for
analysis of large volume of sample solution, typically a few
mL. In contrast, a typical GFAAS requires the injection of a
sample volume of 1-50 µL. From the aspect of sample vol-
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ume, GFAAS is more attractive. Moreover, the invention can
use microfluidic techniques for small volume sample analysis
when the use of small volumes is necessary. Although small
volume samples may be diluted for ICP-MS analysis, dilution
imposes additional steps to carry out bioassays according to
the present invention.
Other than the intrinsic binding affinity of antibody-antigen and any instrumental detection limit, a third factor that
determines the detection limit of the proposed atomic amplification bioassay method is the size and size distribution of
the nanoparticles. As noted above, a larger nanoparticle will
lead to a larger atomic amplification effect, because each
nanoparticle will provide a larger amount of metal or other
ions per labeled nanoparticle. However, when the nanoparticle becomes larger, the conjugation with the target biomolecules can become complicated. Furthermore, Brownian
movement of the nanoparticles in solution can affect the
binding of biomolecules. For different nanoparticles, the
number of metal or other atoms that each particle contains is
determined by the chemical structure and crystalline structure
of the nanoparticles as indicated in Table 2 below. By combining the instrumental detection limit and size of the nanoparticles used in the study, an estimate of the targeting detection limits of the proposed bioassay methods of one
embodiment of the invention was calculated.

This invention is not only aimed at detection, but also
quantitative analysis of biomarker and other biologically
molecules of interest, at ultra low level concentrations.
Because the nanoparticles synthesized using chemical methods are not generally monodispersed, there is a limitation on
the accuracy of the analysis due to the growth of the standard
deviation of the number of gold atoms present as the number
of detected biomolecules increases. The growth in the standard deviation of the number of gold atoms present grows
roughly as the square root of the number of detected biomolecules. An analysis was made of the statistical reliability of a
sample size of 100 nanoparticles (corresponding to the detection of 100 biomolecules) with diameters of 40 nm and 100
nm. As shown in Table 3, below, the half-width of a confidence interval at the 99% accuracy level for a sample size of
100 nanoparticles of 40 nm with a size distribution of 10% is
roughly 7. 74 times the number of gold atoms in an individual
nanoparticle. The comparable datum for a sample of 100
nanoparticles at 100 nm with a size distribution of 5% is 3 .87.
This means using a nanoparticle sample with an average
diameter of 40 nm and a size distribution of 10%, the proposed bioassay method will not allow one to distinguish
100±7 particles (molecules), but can distinguish a sample that
contains about 100 from 150 analyte molecules.
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TABLE2
Structural parameters, instrumental detection limit and estimated bioassay detection limit
using different nanoparticles as probe materials.

Estimated detection limit of the

Size

Nanoparticle

Au

Ag

CdSe

Instrument detection

bioassay

limit

(in absolute number of

Number

(data from Perkin

biomolecules)*

of atoms

Elmer)

GFAAS (10

(diameter

per

GFAAS

ICP-MS

µL sample

ICP-MS (10 mL

in nm)

particle

(ppb)

(ppb)

volume)

sample volume)

40

2 x 10 6

0.15

0.001

10,000s

100,000s

100

3 x 10 7

1000s

10,000s

40

2 x 10 6

lOOs

100,000s

100

3 x 10 7

!Os

10,000s

40

6 x 10 5

lOOs

10,000s

100

1x10 7

!Os

1,000s

0.005

0.002

0.002

0.0001

*The calculation considered different sample volumes used in typical GFAAS (10 µL) and ICP-MS (10 mL) analysis.
The instrument detection limit used in the calculation was 10 times higher than the listed detection limit in the table
to reflect the actual detection limits under usual lab settings. The low-end of the linear dynamic range typically should
be ten times higher than the actual instrument detection limit. The calculation does not consider the biomolecular
binding affinity limit.
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TABLE3
Statistical analysis of the proposed bioassay accuracy using a sample size of 100
nano articles.
Average Size Distribution
nm
Size nm

Average Size
#ofAtoms

Distribution
Size# of atoms

Half width of 99% confidence
interval

40nm

2E8 ± 6E6

2E6 ± 6E5
( ±30%)
3E7 ± 4.5E6
(± 15%)

1.548E7 (7.74 particle)

lOOnm

40 ±4nm
(± 10%)
100±5nm
(±5%)

3E9 ± 4.5E7

1.161E8 (3.87 particles)

To establish an accurate bioassay method for extremely
low level detection of biomolecules (around or less than 100
biomolecules immobilized on the microtiter plate), the dispersion of the nanoparticle size should be well controlled.
Ultracentrifugation, chromatography, or fractional precipitation can be used as needed to increase the monodispersity of
the particle size to increase accuracy. For the detection of
biomolecules at concentration between femto (10- 15 M) to
attomolar (10- 18 M) range, currently available nanoparticles
can be used. The more monodispersed nanoparticle inherently gives the greater accuracy for any given nanoparticle
size. The detection limit of the bioassay using, different
instrumentation (GFAAS versus ICP-MS) and different sized
nanoparticles can be roughly estimated; however detection
limits must be examined and established during development
of any specific assay.
Bioassays according to an embodiment of the invention
can be based on microfluidic devices. Microfluidic devices
permit low sample consumption in the sample analysis. In
addition, microfluidics offer advantages including high surface area-to-volume ratio, fast mass and heat transfer and
improved local control. A high surface area-to-volume ratio is
important for reducing the amount ofbioreagents used for the
bioassays and improve the binding efficiency between biomolecules such as antibody-antigen interactions.
This present method is easy to conduct, accurate, and
affordable. The method can be used by medical labs in hospitals and clinics for diagnosis of disease such as cancer, at
early stages. The method may be used by research labs as a
detection tool to study molecular biology and cellular biology. Some exemplary applications for the present invention
are described below.
Early screening of prostate cancer by the measurement of
Prostate Specific Antigen (PSA) level in blood can be carried
out with detection at lower levels using the atomic amplification effect provided by the current invention. The invention
can be applied to measurement of other serum biomarkers,
such as PSCA, which are found in significantly lower concentrations in serum than that of PSA, prohibiting the potential use of this target by currently used immunohistolochemistry (IHC) and flow cytometry techniques.
The most common methods to detect the cancer biomarkers for breast cancer include IHC, fluorescent in situ hybridization (FISH) and ELISA. Among all the biomarkers, HER2/neu is the most important biomarker for breast cancer
diagnosis, and detection ofHER-2/neu using IHC and FISH
is approved by the FDA. The inventive approach can circumvent many of the current analytical arising from sample consumption and high minimal detection limits. The HER-2/neu
protein can be used as a target protein for assay using the
method of the present invention. Other tumor biomarker
related to breast cancer can also be assayed by the inventive
method.
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The early detection of lung cancer is a problem that
requires improved and more sensitive analytical techniques
such as the amplification method of the present invention.
Table 3 includes a list of lung cancer biomarkers that can be
used as targets with the amplification method for embodiments of the present invention and includes the antibody
clones that can be conjugated with the nanoparticies of the
probe and bind to the biomarker.
TABLE3
Lllilg cancer biomarkers and their relative antibodies
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Biomarker

Antibody clone

CA125
VEGF
s!L-2R-alpha
MIF
CDC6
Cytokeratin 7
Cytokeratin 8
Cytokeratin 18
Cytokeratin 19
ER-beta
ER alpha
Osteopontin
y-histone H2AX

OC125
Ab array
Ab array
hMIF (12302)
37F4
OV-TL 12/30
35i)Hll
DClO
RCK 108
N-19
D-12
Anti-Human 0-17
p-H2A.X (Ser139)

In an embodiment of the invention, the nanoparticles synthesized contain surface carboxylic acid groups, and amide
coupling using EDC/NHS can be used to conjugate antibody
to the nanoparticles. The conjugated nanoprobes can be purified by centrifugation or size exclusion chromatography to
eliminate unconjugated antibody, streptavidin, or other
chemical reagents.
Although the present invention has been described above
for ultra sensitive bioassays for the detection and quantitative
analysis of cancer-related biomarkermolecules, it is clearthat
the methodology can be applied for other biologically relevant molecules, as well as viruses and organisms. Gold
nanoparticles have been used as a contrast agent for tracing
the location of proteins in biological cells using electron
microscopy, however, revealing only qualitative information
and not the amount of the target proteins in a cell. By decomposing the gold nanoparticles attached to the proteins and
analyzing the gold ion concentration according to an embodiment of the invention, one can obtain quantitative information
on the protein in a sample.
A system for carrying out the inventive method to determining the presence of biomolecule targets can be constructed having a vessel where a sample solution suspected of
containing the targets can be combined with a plurality of
bioreceptor functionalized nanoparticle probes. The vessel
has a solid substrate to permit the separation of probes bound
to targets from probes free of targets. In one embodiment of
the system a substrate for selectively binding targets-probe
conjugates is included. In another embodiment of the inven-
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tion the included substrate can selectively bind target free
probes. The vessel can have the substrate present before introduction of the sample solution and the probes or it can be
introduced after contacting the probes with the sample solution. The substrate can be a surface of a plate or a particulate
material where in one embodiment of the invention the surface of the substrate has moieties for selective binding with
the target biomolecule and ultimately a target-probe conjugate. In another embodiment of the invention the surface has
moieties for selectively binding to probes that are not conjugated with the targets. In one embodiment of the invention the
vessel can be the substrate in a plate form.
The system also includes a separation device to separate
the substrate from the remaining complementary solution of
unbound probes, which are either free probes or target-probe
conjugates. In one embodiment the device can be a holder for
a plate substrate such that the complementary solution can be
washed from the substrate bound to the target-probe conjugate. In another embodiment the separation device can be a
filter where the complementary solution can be filtered from
the particulate substrate. In other embodiments the separation
device can be a centrifuge or a chromatography column.
The system also includes a reagent for breaking down the
nanoparticles of the probes to generate the signal moieties
that allow the ultimate analysis to occur with amplification
from one given signal from a single target to a plurality of
signals that can be related to the presence of a single target.
The probes to be broken down can be either of or both of the
groups of probes attached ultimately to the substrate or
probes in the complementary solution. An exemplary reagent
is an oxidizing reagent for the conversion of metal nanoparticles into a plurality of metal ions. In one embodiment of the
invention both groups of probes, those with and those without
bound targets can be separately broken down with reagents to
generate signal moieties.
The system also includes a device to measure a parameter
of the solution or solutions of signal moieties. For example,
the device can be a spectrometer such as an ICP-MS or
GFAAS. The system can be adapted to detect a plurality of
targets simultaneously by the inclusion of a plurality of
probes forthe plurality of targets. A plurality of substrates for
selective binding the plurality of probes or target-probe conjugates can be included in the system. For example two plates
can be included in a vessel where the two plates selectively
bind to two different target-probe conjugates or where one
target is present and one plate binds to target-probe conjugates and the other plate binds to target free pro bes. In another
embodiment of the invention different probes can have different nanoparticles with the same or different bioreceptors
for different targets where the different nanoparticles can be
simultaneously broken down to simultaneously detect different signal moieties. For example, one probe can have a gold
nanoparticle and a second can have a silver nanoparticle with
different bioreceptors so that upon oxidation to the signal
moieties gold ions can indicate the presence or concentration
of one target and silver ions can indicate the presence of a
second target.
FIG. 1 illustrates a conceptual system of an embodiment of
the invention where the components of the system are physically connected. Embodiments of the inventive system do not
require that the components be physically linked together or
be of the type inferred in FIG. 1. Various types of components
of the system can be used and solutions and solids can be
transferred between components manually or in an automated
fashion, which is not illustrated. In FIG. 1 the system 100 of
one embodiment of the invention includes a vessel 106 where
a particular substrate 108 is mixed with a sample solution and

a probe solution or suspension through ports 102and104. In
other embodiments only one means of entry to the vessel is
required. After the sample solution, probes and substrate 108
have been combined for a sufficient period of time for the
target-probe conjugate and the binding of eitherthe conjugate
or the free probes to form in vessel 106, the bound substrate
can be separated from the complementary liquid by the use of
the separation device 110, which can be a filter as shown. As
illustrated for system 100, the complementary solution flows
into a second vessel 114 where a break down reagent can be
introduced through port 112 to decompose the nanoparticles
of the probe into the signal moieties and be in communication
with a sample cell 118 ofa device to measure a parameter 116,
which for illustration purposes is shown essentially as an
optical spectrometer where a light source 120 transmits light
through the sample cell 118 to a detector 122 which sends an
electrical signal to a processor or converter 124 to provide an
output that can be interpreted by an individual assessing the
results with respect to the presence or concentration of the
target in the sample solution.
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EXAMPLES
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It should be understood that the Examples described below
are provided for illustrative purposes only and do not in any
way define the scope of the invention.
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Currently, GFAAS and ICP-MS are the two most sensitive
techniques for ultra trace metal analysis. The detection limit
of GFAAS was examined on gold nanoparticles. A citrate
stabilizednanoparticles with an average core diameter around
35 nm were decomposed by a solution ofliKI, where the I 2
oxidizes gold atoms from the nanoparticles into gold ions.
This solution was then diluted into four concentrations ranging from 10- 11 to 10- 15 M. This nanoparticle concentration
range corresponds to a gold ion concentration ranging from
10- 5 to 10- 9 M. The analysis of 20 µL samples demonstrated
that the lowest concentration of gold ions that can be detected
by GFAAS is atthe orderofl o-s Mas analyzed using a Perkin
Elmer AAalyst 600 instrument, resulting from a gold nanoparticle concentration of 10- 14 M (10 s of femtomolar).
Therefore, the minimal number of gold nanoparticles that can
be detected by GFAAS is approximately 10,000.
Similar analysis was conducted on silver nanoparticles
using ICP-MS technique. Citrate-stabilized silver colloids
were purchased from Ted Pella, Inc. The nanoparticles were
decomposed into silver ions using I2 /KI solution. Using ICPMS technique, the lowest concentration of silver ions
detected was 20 ppt, corresponding to a silver nanoparticle
concentration of 10- 16 M.
Example 2
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PSA is a 32 kDa single chain glycoprotein serine protease
with a chymotrypsin like specificity produced by the secretory epithelium of the prostate gland. PSA that is normally
secreted into the seminal fluid plays a functional role in the
cleavage of the seminal vesicle proteins and the liquefaction
of the seminal coagulum. Only low levels of PSA are normally present in the blood stream, and increasing serum concentrations indicate prostatic pathology, including benign
prostatic hyperplasia and cancer of the prostate. Determination of PSA is now widely used for detection and management of patients with pro static cancer and considered as the
superior serological marker for cancer of the prostate. The
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atomic amplification assay approach was used to examine the
detection of PSA and compared the results with standard
ELISA assay.
A commercial ELISA kit for PSA assay along with a paired
detector antibody was purchased from Ano Gen, Inc. We conducted PSA assay using the ELISA kit and obtained a linear
calibration curve. This assay kit uses horseradish peroxidase
as the detector antibody label. The detector antibodies were
labeled using the citrate-stabilized gold nanoparticles.
Citrate-stabilized gold nanoparticles with an average
diameter of 40 urn were synthesized according to Turkevich
et al. Discuss. Faraday Soc., 11 (1951) 55. The size distribution of the nanoparticles was determined by transmission
electron microscopy to be 43±3.5 nm, with a size distribution
around or less than 10%. According calculations from this
laboratory, Liu et al., Colloids and Surfaces B: Biointerfaces,
58 (2007) 3-7, the number of gold atoms in each particle is
around 2 million.
The labeling was conducted according to the following
procedure. An excessive amount of antibody (100 fold excess
of antibody versus gold nanoparticle) was mixed with gold
nanoparticles and incubated at room temperature for one
hour. Unlabeled antibodies were then separated from labeled
conjugate using size exclusion chromatography. The concentration of the labeled gold nanoparticles was determined by
UV-Vis absorption spectroscopy and calculated according to
the solution absorbance using an equation developed in Liu et
al.
The ELISA assay using the gold nanoparticle conjugated
detector antibody followed the same procedure as typical
ELISA assay. After antigen binding and washing cycles, the
gold nanoparticles were decomposed using 2 mL I2 /KI solution and the gold ion concentration was analyzed by GFAAS.
FIG. 2 includes plots of gold ion concentration versus PSA
concentration obtained from different assays. Results showed
that the atomic amplification assay can detect PSA at concentration as low as 10-100 pg/mL. According to the volume of
PSA antigen solution used for the assay (100 µL ), and sample
injection volume for GFAAS analysis (20 µL from the 2 mL
of prepared solution), it is calculated that the AAA assay can
detect PSA in the absolute mass ofrange 0.02-0.2 pg, corresponding to approximately 10- 13 to 10- 19 mo! of PSA which
is the detection limit calculated and given in Table 1. Furthermore, a linear relationship exists between gold ion and PSA in
the concentration range of 10-1000 pg/mL. FIG. 3 is a plot of
two different series of assays conducted in two different laboratories using PSA antibody and assay plates from two different commercial sources. From this comparison, one can
see that the reproducibility of the results is fairly good even
though no effort was made to optimize bioassay conditions
and atomic absorption analysis parameters.

nanoparticles are then activated with EDC (N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide) and NHS (N-hydroxysuccinimide). Two types of oligo(ethylene glycol) amine
ligands, one with two amino end groups and one with a single
amine end group, as shown in FIG. 4, are then coupled to the
nanoparticles. The ratio of the two ligands can be adjusted to
control the percentage of free amino groups modified on the
nanoparticle surface. The free amino groups exposed on the
nanoparticle surface will then be converted to carboxylic acid
group by reaction with maleic anhydride. At this point, the
nanoparticles can be couple with streptavidin or other detector antibody to prepare the conjugate probes.
Highly mono-dispersed CdSe nanoparticles can be synthesized at high temperature using CdC0 3 and selenium powder
as key reagents, with TOPO (trioctylphosphine oxide) and
stearic acid as surfactants. This method can be used to synthesize CdSe nanoparticles from 4 to 25 nm with good monodispersity (5%-10%). To improve the fluorescence quantum
yield of those quantum dots and prevent them from photooxidation, a CdS shell layer can be deposited on the CdSe
core surface as a passivation layer. This step can be done by
slowly dropping a mixture solution of (TMS) 2 S (bis-trimethylsilane sulfide) and Cd(CH 3 ) 2 (dimethylcadmium) in TBP
(tributylphosphine). A thiol ligand place exchange reaction
can be used to substitute the original TOPO and stearic acid
capping ligands with 2-mercaptosuccinic acid (MSA) ligand
or thioctic acid. MSA-protected CdSe nanoparticles can then
be converted to the probes using the route as illustrated in
FIG. 4 for gold nanoparticles. Other methods can be used for
the preparation of larger CdSe particles.
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Example 3
A route to nanoparticle probes according to an embodiment of the invention is given in FIG. 4. Relatively monodispersed citrate-stabilized gold nanoparticles can be synthesized using the method ofTurkevich et al. in aqueous solution
with sizes ranging from 10-120 nm, by controlling the volume of the capping ligand, tri-sodium citrate. The synthesis of
citrate-stabilized silver nanoparticles can be done using by
using silver nitrate as in Lee et al. J. Phys. Chem. 86 (1982)
3391. After purification, citrate-stabilized gold or silver nanoparticles will be converted to thioctic acid-protectednanoparticles through the ligand place exchange reaction. Two thiol
groups-terminated thioctic acid is used to provide structural
stability to the nanoparticles. The carboxyl groups on the

55

PSA assay using quantum dot nanoprobes (QDs) was also
carried out. Streptavidin-conjugated quantum dots with an
average size of 5-8 nm were purchased from Invitrogen, Inc.
An assay was conducted using an ELISA format and biotinconjugated detector antibody and streptavidin QDs were
added to conjugate with the detector antibody. The QDs
bound to the microtiter plate were decomposed using a bromine solution. Decomposed QDs solution was then subjected
to Cd ion analysis using an inductive coupled plasma mass
spectrometer.
FIG. 5 is a plot of Cd ion concentration versus PSA concentration. At ng/mL range, a linear relation was found from
the PSA concentration versus Cd ion concentration. The QDs
used in the current study have a core size of 5 nm. The
amplification effect is limited to the order of 1,000 times less
than a 40 nm gold nanoparticle. For the control sample with
no PSA antigen present in the sample solution, a high level of
Cd ion of0.19 ppb was detected. The detection limit of the
ICP-MS instrument used in this study for Cd ions is 0.001
ppb. The detected Cd ion level from the control sample is
much above the instrumental detection limit indicating
absorption of the Cd by the ELISA plate without the PSA
target.
Example 5
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Anti-cytokeratine antibody was conjugated to a 40 nm
citrate-stabilized gold nanoparticle similarly to the conjugation of anti-PSA antibody as described above. An ELISA
assay to detect cytokeratine from a lysed cell sample was
conducted with these probes. Capture antibodies were immobilized on ELISA plates in three different concentration, 0.16,
1.6, and 16 µg/mL. The lysed cell samples were then added to
the microwells of the plates. After incubation and washing
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cycle, antibody-gold nanoparticle conjugates were added to
the plate in one concentration. The microtiter plate-bound
gold nanoparticles were then decomposed using a 2 mL IiKI
solution and the solution and subjected to gold ion concentration analysis. FIG. 6 is a plot of the measured gold ion
concentration from the assayed samples versus capture antibody concentration. The plot clearly exhibits an increasing,
although not linear, gold ion concentration with increased
capture antibody concentration. Monoclonal anti-pan cytokeratine mixture of clones C-11, PCK-26, CY-90, KS-1A3,
M20, A53-B/A2 (Sigma, MO) as the substrate bound antibody and monoclonal anti-cytokeratine 8, clone M20 (Sigma,
MO) was used as the probe antibody.
This invention can be embodied in other forms without
departing from the spirit or essential attributes thereof and,
accordingly, reference should be to the following claims
rather than the foregoing specification as indicating the scope
of the invention. The Abstract of the Disclosure is provided to
comply with 37 C.F.R. §1.72(b), requiring an abstract that
will allow the reader to quickly ascertain the nature of the
technical disclosure. It is submitted with the understanding
that it will not be used to interpret or limit the scope or
meaning of the following claims.
We claim:
1. A method for detection of biomolecule targets, comprising the steps of:
providing a probe solution comprising a plurality of probes
comprising bioreceptor functionalized nanoparticles,
wherein said nanoparticles consisting of a plurality of
metal atoms, and wherein said bioreceptor is adapted for
binding said probes to said targets;
contacting a sample solution suspected of including said
targets with said probe solution comprising said plurality of probes, wherein said targets when present in said
sample solution bind to said plurality of probes;
separating said plurality of probes into a first group of
probes having said targets bound thereto and a second
group of probes not having said targets bound thereto;
breaking down said nanoparticles associated with probes
in at least one of said groups of probes, wherein a plurality of signal moieties are released for each of said
nanoparticles that are broken down to form at least one
signal moiety solution;
measuring a parameter of said signal moieties in said at
least one signal moiety solution; and
determining a presence of said targets in said sample solution from said parameter of said signal moieties.
2. The method of claim 1, wherein said signal moieties
comprise ions, discrete radioactive isotopes or discrete fluorescent dye molecules.
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3. The method of claim 1, wherein said breaking down step
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comprises oxidizing said plurality of metal atoms into metal
10ns.
4. The method of claim 3, wherein said metal atoms are
selected from the group consisting of gold, silver, cadmium
and an alloy thereof.
5. The method of claim 1, wherein said bioreceptor comprises at least one selected from the group consisting of antibody, DNA, proteins including enzymes, cells or cell components.
6. The method of claim 1, wherein said target comprises at
least one biomarker of at least one type of cancer.
7. The method of claim 1, wherein said sample solution
comprises a bodily fluid or a fluid derived from body tissue.
8. The method of claim 1, wherein said step of separating
comprises binding said targets to a substrate surface before
contacting said targets with said probes and separating said
substrate from said probes not having said target bound
thereto, wherein said probes not having said target bound
thereto are in solution.
9. The method of claim 1, wherein said step of separating
comprises binding said probes not having said targets bound
thereto to a substrate surface after contacting said targets with
said probes and separating said substrate from said probes
having said target bound thereto, wherein said probes having
said target bound thereto are in solution.
10. The method of claim 1, wherein said step of measuring
a parameter comprises measuring a concentration of ions in
said signal moiety solution by atomic absorption spectroscopy.
11. The method of claim 1, wherein said step of measuring
a parameter comprises measuring a concentration of ions in
said signal moiety solution by mass spectroscopy.
12. The method of claim 1, wherein said determining a
presence of said target in said sample solution comprises
calculations using values for an average size of said nanoparticles and an average number of said bioreceptors attached to
each of said probes.
13. The method of claim 12, wherein said determining the
presence comprises calculations using a value for said parameter of said signal moieties wherein said signal moiety solution results from breaking down said probes having said target
bound thereto.
14. The method of claim 12, wherein said determining the
presence comprises calculations using a value for said parameter of said signal moieties wherein said signal moiety solution results from breaking down said probes not having said
target bound thereto and using a value for a concentration of
said probes contacted with said sample solution.
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